Taking all these data together, we demonstrated the critical role played by CyPA/EMMPRIN axis in the modulation of MFS-related key pathway activation and gene expression, providing a proof-of-concept that the blockage of this axis may offer a novel therapeutic target to treat TAA in MFS patients. This evidence concerns the gene BSG and Marfan syndrome.